Dauch Corp
3 ballot items.
Three proposals will be voted on: (1) Charter Amendment to increase authorized AAM Shares from 150,000,000 to 375,000,000; (2) Share Issuance to Dowlais Shareholders of about 117,000,000 New AAM Shares as stock consideration in the Combination; and (3) Adjournment of the Special Meeting to solicit additional proxies.
Follow how the vote landed and what changed on Dauch Corp’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
On the ballot3
- 1
Charter Amendment to increase the number of authorized AAM Shares
ManagementBoard: FORAmends the certificate of incorporation to increase authorized common shares from 150,000,000 to 375,000,000 to enable issuance of New AAM Shares to Dowlais Shareholders and provide flexibility for future issuances.
- 2
Share Issuance Proposal
ManagementBoard: FORApprove issuance of approximately 117,000,000 New AAM Shares to Dowlais Shareholders in connection with the Combination, with Dowlais Shareholders owning about 49% of AAM’s fully diluted common stock.
- 3
Adjournment Proposal
ManagementBoard: FORAdjourn the Special Meeting to a later date or time to solicit additional proxies if there are insufficient votes at the time of such adjournment to approve the Charter Amendment or the Share Issuance.
Nominees on the ballot
Top institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | BlackRock, Inc. | 10.4% | 24,672,148 | $146M |
| 2 | FMR LLC | 4.3% | 10,143,498 | $60M |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 4.2% | 9,991,639 | $59M |
| 4 | STATE STREET CORP | 3.8% | 9,022,577 | $54M |
| 5 | BlackRock, Inc. | 3.4% | 8,089,465 | $48M |
| 6 | GOLDMAN SACHS GROUP INC | 3.2% | 7,635,294 | $45M |
| 7 | DIMENSIONAL FUND ADVISORS LP | 3.1% | 7,432,444 | $44M |
| 8 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2.4% | 5,776,256 | $34M |
| 9 | DME Capital Management, LP | 2.3% | 5,498,360 | $33M |
| 10 | HIGHLAND PEAK CAPITAL, LLC | 2.2% | 5,144,616 | $31M |
Other Consumer Cyclical sector meetings6
Upcoming shareholder meetings at Dauch Corp’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Frequently asked questions
- When is the Dauch Corp 2025 special meeting?
- Dauch Corp (DCH) holds its 2025 special shareholder meeting on Tuesday, July 15, 2025.
- What is the record date for the Dauch Corp 2025 meeting?
- The record date for the Dauch Corp 2025 meeting is Monday, June 9, 2025. Shareholders of record on or before that date are eligible to vote.
- What proposals will shareholders vote on at the Dauch Corp 2025 meeting?
- Shareholders will vote on 3 proposals at the Dauch Corp 2025 meeting, each tagged with who proposed it and the board's recommendation.
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.